Evoke Pharma Inc Drug Patent Portfolio
Evoke Pharma Inc owns 1 orange book drug protected by 7 US patents Given below is the list of Evoke Pharma Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334281 | Nasal formulations of metoclopramide | 16 May, 2030 | Active |
| US11020361 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11628150 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11813231 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194008 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194009 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis | 29 Mar, 2021 | Expired |
Latest Legal Activities on Evoke Pharma Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Evoke Pharma Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jun, 2024 | US8334281 |
|
Email Notification
Critical
| 08 Dec, 2023 | US8334281 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Dec, 2023 | US8334281 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11020361 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11813231 |
|
Email Notification
Critical
| 01 Dec, 2023 | US11628150 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11813231 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11628150 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Dec, 2023 | US11020361 |
| Mail Patent eGrant Notification | 14 Nov, 2023 | US11813231 |
|
Email Notification
Critical
| 14 Nov, 2023 | US11813231 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Nov, 2023 | US11813231 |
| Recordation of Patent eGrant | 14 Nov, 2023 | US11813231 |
| Patent eGrant Notification | 14 Nov, 2023 | US11813231 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Nov, 2023 | US11813231 |
Evoke Pharma Inc's Family Patents
Evoke Pharma Inc Drug List
Given below is the complete list of Evoke Pharma Inc's drugs and the patents protecting them.
1. Gimoti
Gimoti is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8334281 | Nasal formulations of metoclopramide |
16 May, 2030
(5 years from now)
| Active |
| US11020361 | Nasal formulations of metoclopramide |
22 Dec, 2029
(4 years from now)
| Active |
| US11628150 | Nasal formulations of metoclopramide |
22 Dec, 2029
(4 years from now)
| Active |
| US11813231 | Nasal formulations of metoclopramide |
22 Dec, 2029
(4 years from now)
| Active |
| US12194008 | Nasal formulations of metoclopramide |
22 Dec, 2029
(4 years from now)
| Active |
| US12194009 | Nasal formulations of metoclopramide |
22 Dec, 2029
(4 years from now)
| Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis |
29 Mar, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gimoti's drug page